Clene Inc. outlined an ambitious development timeline for CNM-Au8, its investigational treatment for amyotrophic lateral sclerosis, in a stockholder communication detailing key regulatory milestones expected throughout 2026. The company plans to conduct an FDA Type C meeting by the first quarter, submit a new drug application via the accelerated approval pathway in the second quarter, and potentially receive a PDUFA decision date by the second half of the year. These regulatory interactions follow clinical data from over 800 treated ALS patients showing prolonged survival benefits and a favorable safety profile.
Clene secured $28 million in funding that extends the company's operational runway through the fourth quarter of 2026, providing sufficient capital to execute its planned regulatory strategy. Beyond the NDA submission, the company intends to initiate a Phase 3 confirmatory trial later in 2026, positioning the program for continued advancement regardless of the FDA's accelerated approval decision.
The timeline reflects the regulatory pathway available for treatments addressing ALS, a neurodegenerative disease with limited therapeutic options. Success in achieving these milestones would represent significant progress toward bringing a potential new treatment option to patients, contingent on FDA review and approval decisions.